Palisade FDA Clears IND for IBD Treatment PALI-2108

Palisade Bio secured FDA clearance to advance its Phase 2 ASCENTRA trials for the IBD treatment PALI-2108, showcasing strong clinical data from its first study. This progression highlights the company's advancing pipeline following encouraging results in ulcerative colitis and Crohn's disease.